Early Friday morning, Osiris Therapeutics, which is developing stem cell therapies for inflammatory, orthopedic and cardiovascular disorders, announced the completion of its 3.5 million share IPO. The deal priced at $11 per share, the low end of its proposed $11 to $13 price range. Jefferies was the lead underwriter on the deal. The stock is expected to being trading on the NASDAQ under the ticker OSIR on Friday.
